LEXICON PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.905 USD | +1.87% |
|
+6.78% | +23.53% |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to the Lexicon Pha...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.87
USD
Average target price
5.25
USD
Spread / Average Target
+180.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.53% | 676M | |
| +4.16% | 111B | |
| +11.45% | 105B | |
| -13.00% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.29% | 16.96B | |
| +3.42% | 13.7B | |
| +37.06% | 12.45B |
- Stock Market
- Equities
- LXRX Stock
- News Lexicon Pharmaceuticals, Inc.
- Transcript : Lexicon Pharmaceuticals, Inc., Q4 2022 Earnings Call, Mar 02, 2023
